These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 8637717

  • 1. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.
    Chen IT, Akamatsu M, Smith ML, Lung FD, Duba D, Roller PP, Fornace AJ, O'Connor PM.
    Oncogene; 1996 Feb 01; 12(3):595-607. PubMed ID: 8637717
    [Abstract] [Full Text] [Related]

  • 2. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
    Fotedar R, Fitzgerald P, Rousselle T, Cannella D, Dorée M, Messier H, Fotedar A.
    Oncogene; 1996 May 16; 12(10):2155-64. PubMed ID: 8668341
    [Abstract] [Full Text] [Related]

  • 3. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
    Rousseau D, Cannella D, Boulaire J, Fitzgerald P, Fotedar A, Fotedar R.
    Oncogene; 1999 May 27; 18(21):3290-302. PubMed ID: 10359535
    [Abstract] [Full Text] [Related]

  • 4. Hyperoxia induces S-phase cell-cycle arrest and p21(Cip1/Waf1)-independent Cdk2 inhibition in human carcinoma T47D-H3 cells.
    Bilodeau JF, Faure R, Piedboeuf B, Mirault ME.
    Exp Cell Res; 2000 May 01; 256(2):347-57. PubMed ID: 10772807
    [Abstract] [Full Text] [Related]

  • 5. Deregulation of p53/p21Cip1/Waf1 pathway contributes to polyploidy and apoptosis of E1A+cHa-ras transformed cells after gamma-irradiation.
    Bulavin DV, Tararova ND, Aksenov ND, Pospelov VA, Pospelova TV.
    Oncogene; 1999 Oct 07; 18(41):5611-9. PubMed ID: 10523840
    [Abstract] [Full Text] [Related]

  • 6. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1.
    Luo Y, Hurwitz J, Massagué J.
    Nature; 1995 May 11; 375(6527):159-61. PubMed ID: 7753174
    [Abstract] [Full Text] [Related]

  • 7. Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor.
    Goubin F, Ducommun B.
    Oncogene; 1995 Jun 15; 10(12):2281-7. PubMed ID: 7784076
    [Abstract] [Full Text] [Related]

  • 8. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
    Orend G, Hunter T, Ruoslahti E.
    Oncogene; 1998 May 15; 16(20):2575-83. PubMed ID: 9632134
    [Abstract] [Full Text] [Related]

  • 9. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
    Sandhu C, Donovan J, Bhattacharya N, Stampfer M, Worland P, Slingerland J.
    Oncogene; 2000 Nov 09; 19(47):5314-23. PubMed ID: 11103932
    [Abstract] [Full Text] [Related]

  • 10. Identification of a p130 domain mediating interactions with cyclin A/cdk 2 and cyclin E/cdk 2 complexes.
    Lacy S, Whyte P.
    Oncogene; 1997 May 22; 14(20):2395-406. PubMed ID: 9188854
    [Abstract] [Full Text] [Related]

  • 11. Expression of a novel form of p21Cip1/Waf1 in UV-irradiated and transformed cells.
    Poon RY, Hunter T.
    Oncogene; 1998 Mar 12; 16(10):1333-43. PubMed ID: 9546435
    [Abstract] [Full Text] [Related]

  • 12. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
    Rao S, Lowe M, Herliczek TW, Keyomarsi K.
    Oncogene; 1998 Nov 05; 17(18):2393-402. PubMed ID: 9811471
    [Abstract] [Full Text] [Related]

  • 13. Cloning and characterization of a novel p21(Cip1/Waf1)-interacting zinc finger protein, ciz1.
    Mitsui K, Matsumoto A, Ohtsuka S, Ohtsubo M, Yoshimura A.
    Biochem Biophys Res Commun; 1999 Oct 22; 264(2):457-64. PubMed ID: 10529385
    [Abstract] [Full Text] [Related]

  • 14. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
    Rousseau D, Cannella D, Boulaire J, Fitzgerald P, Fotedar A, Fotedar R.
    Oncogene; 1999 Jul 29; 18(30):4313-25. PubMed ID: 10439039
    [Abstract] [Full Text] [Related]

  • 15. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells.
    Gong J, Ammanamanchi S, Ko TC, Brattain MG.
    Cancer Res; 2003 Jun 15; 63(12):3340-6. PubMed ID: 12810668
    [Abstract] [Full Text] [Related]

  • 16. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21.
    Li Y, Jenkins CW, Nichols MA, Xiong Y.
    Oncogene; 1994 Aug 15; 9(8):2261-8. PubMed ID: 7913544
    [Abstract] [Full Text] [Related]

  • 17. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells.
    Lu Y, Yamagishi N, Yagi T, Takebe H.
    Oncogene; 1998 Feb 12; 16(6):705-12. PubMed ID: 9488034
    [Abstract] [Full Text] [Related]

  • 18. Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints.
    Xie G, Habbersett RC, Jia Y, Peterson SR, Lehnert BE, Bradbury EM, D'Anna JA.
    Oncogene; 1998 Feb 12; 16(6):721-36. PubMed ID: 9488036
    [Abstract] [Full Text] [Related]

  • 19. Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells.
    Sekiguchi T, Hunter T.
    Oncogene; 1998 Jan 22; 16(3):369-80. PubMed ID: 9467962
    [Abstract] [Full Text] [Related]

  • 20. TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase.
    Ono T, Kitaura H, Ugai H, Murata T, Yokoyama KK, Iguchi-Ariga SM, Ariga H.
    J Biol Chem; 2000 Oct 06; 275(40):31145-54. PubMed ID: 10878006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.